Published in Gene Therapy Weekly, November 15th, 1999
"To develop models of human cancer we have expressed the avian retroviral receptor, TVA, under a variety of mammalian promoters in transgenic mice, thus rendering mice susceptible to infection with avian leukosis virus-derived gene vectors," stated G.H. Fisher and colleagues, from the U.S. National Cancer Institute, Varmus Laboratory, Bethesda, Maryland. "TVA-based retroviral gene transfer offers advantages over current murine models of human cancer."
Fisher et al. published the results of their study in Oncogene...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.